Azanta
Markets and distributes pharmaceutical products.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 27 % | 14 % | - | - | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (21 %) | (20 %) | - | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (13 %) | (10 %) | - | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Azanta A/S, now a wholly owned subsidiary of Norgine B.V., operates in the pharmaceutical industry, focusing on specialized healthcare solutions. The company serves a diverse range of clients, including healthcare professionals and institutions, primarily in the fields of obstetrics, mucosal protection, and addiction medicine. Azanta's market presence spans across Europe, Australia, and New Zealand, leveraging Norgine's extensive distribution network to bring its products to market effectively. The business model revolves around the development, acquisition, and distribution of niche pharmaceutical products. Revenue is generated through the sales of these specialized medications, which address specific medical needs that are often underserved by larger pharmaceutical companies.
Keywords: pharmaceutical, obstetrics, mucosal protection, addiction medicine, healthcare, niche products, Europe, Australia, New Zealand, distribution.